Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current HIV Research
  4. Fast Track Articles
  5. Fast Track Article
image of Prevalence of Metabolic Syndrome in Iranian Adults Receiving Antiretroviral Treatment for HIV

Abstract

Background

The increased risk of metabolic syndrome (MetS) and its subcomponents among people living with HIV/AIDS, especially in developing countries, is well documented with the global pooled prevalence of the related risk factors in this population.

Objective

This study aimed to explore the prevalence of MetS among Iranian People living with HIV according to the ATP III and Iranian criteria.

Methods

The cross-sectional study was conducted on consecutive patients who visited THE referral centre for AIDS/HIV between May to December 2023. A total of 130 participants (n=83; 63.8% male) were investigated based on the inclusion criteria, which included having a minimum age of 25 and a maximum of 65 years and following a stable ART treatment regimen for at least six months. A Chi-square test was used to determine the relationship between the categorical variables. Uni/Multi-variable linear regression analysis was used to quantify the associations between MetS and HIV by the independent variables.

Results

The incidence of MetS according to ATP III and Iranian criteria were 42 (32.3%) and 45 (34.6%), which was higher in older patients (p=0.001) and those with more duration since HIV diagnosis (p=0.02). Around 33.1% and 16.1% were overweight and obese, respectively. Among the components of MetS, the highest prevalence (50.8%) was related to low HDL, and the lowest was related to fasting blood sugar (21.5%). The average body fat mass, protein mass, Soft lean mass, and percentage body fat were 18.54±9.46 kg, 10.91±2.17 kg, 51.31±9.61 kg, and 24.86±10.25% that were higher in MetS group (p<0.05).

Conclusion

Our study points out the high prevalence of MetS in an Iranian population living with HIV, especially those suffering from the underlying disease for a longer time. Conducting multi-centric studies with larger sample sizes is needed to confirm our results and determine the most effective measures.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X340090250204072449
2025-02-11
2025-05-06

  • From This Site

    /content/journals/chr/10.2174/011570162X340090250204072449
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Saklayen M.G. The global epidemic of the metabolic syndrome. Curr. Hypertens. Rep. 2018 20 2 12 10.1007/s11906‑018‑0812‑z 29480368
    [Google Scholar]
  2. Cameron A.J. Shaw J.E. Zimmet P.Z. The metabolic syndrome: Prevalence in worldwide populations. Endocrinol. Metab. Clin. North Am. 2004 33 2 351 375 10.1016/j.ecl.2004.03.005 15158523
    [Google Scholar]
  3. Gundogan K. Bayram F. Gedik V. Kaya A. Karaman A. Demir Ö. Sabuncu T. Kocer D. Coskun R. Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults. Arch. Med. Sci. 2013 2 2 243 253 10.5114/aoms.2013.34560 23671434
    [Google Scholar]
  4. Aguilar M. Bhuket T. Torres S. Liu B. Wong R.J. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA 2015 313 19 1973 1974 10.1001/jama.2015.4260 25988468
    [Google Scholar]
  5. Pan W.H. Yeh W.T. Weng L.C. Epidemiology of metabolic syndrome in Asia. Asia Pac. J. Clin. Nutr. 2008 17 Suppl. 1 37 42 18296297
    [Google Scholar]
  6. Azizi F. Khalili D. Aghajani H. Esteghamati A. Hosseinpanah F. Delavari A. Larijani B. Mirmiran P. Mehrabi Y. Kelishadi R. Hadaegh F. Appropriate waist circumference cut-off points among Iranian adults: The first report of the Iranian National committee of obesity. Arch. Iran Med. 2010 13 3 243 244 20433230
    [Google Scholar]
  7. Sadrbafoghi S.M. Salari M. Rafiee M. Namayandeh S. M, and Abdoli A. M, and Karimi M and FSK. Prevalence and criteria of metabolic syndrome in an urban population: Yazd Healthy Heart Project (article) Author. Tehran Univ. Med. J. 2006 64 10 90 96
    [Google Scholar]
  8. Shahbazian M. Jacobs R. Wyatt J. Denys D. Lambrichts I. Vinckier F. Willems G. Validation of the cone beam computed tomography–based stereolithographic surgical guide aiding autotransplantation of teeth: Clinical case–control study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2013 115 5 667 675 10.1016/j.oooo.2013.01.025 23601222
    [Google Scholar]
  9. Govender R.D. Hashim M.J. Khan M.A.B. Mustafa H. Khan G. Global epidemiology of HIV/AIDS: A resurgence in North America and Europe. J. Epidemiol. Glob. Health 2021 11 3 296 301 10.2991/jegh.k.210621.001 34270183
    [Google Scholar]
  10. The Global HIV/AIDS Epidemic. 2024 Available from: https://www.kff.org/global-health-policy/fact-sheet/the-global-hiv-aids-epidemic/
  11. Chhoun P. Tuot S. Harries A.D. Kyaw N.T.T. Pal K. Mun P. High prevalence of non-communicable diseases and associated risk factors amongst adults living with HIV in Cambodia. PLoS One 2017 12 11 e0187591 10.1371/journal.pone.0187591
    [Google Scholar]
  12. Hyle E.P. Naidoo K. Su A.E. El-Sadr W.M. Freedberg K.A. HIV, tuberculosis, and noncommunicable diseases: What is known about the costs, effects, and cost-effectiveness of integrated care? J Acquir Immune Defic Syndr 2014 67 Suppl 1 S87 S95
    [Google Scholar]
  13. Jones C.Y. Metabolic syndrome in HIV-infected patients: No different than the general population? Clin. Infect. Dis. 2007 44 5 735 738 10.1086/511691 17278069
    [Google Scholar]
  14. Freitas P. Carvalho D. Souto S. Santos A.C. Xerinda S. Marques R. Martinez E. Sarmento A. Medina J.L. Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients. BMC Infect. Dis. 2011 11 1 246 10.1186/1471‑2334‑11‑246 21933422
    [Google Scholar]
  15. Alvarez C. Salazar R. Galindez J. Rangel F. Castañeda M.L. Lopardo G. Cuhna C.A. Roldan Y. Sussman O. Gutierrez G. Cure-Bolt N. Seas C. Carcamo C. Castrillo M. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Braz. J. Infect. Dis. 2010 14 3 256 263 10.1016/S1413‑8670(10)70053‑2 20835509
    [Google Scholar]
  16. Bosho D.D. Dube L. Mega T.A. Adare D.A. Tesfaye M.G. Eshetie T.C. Prevalence and predictors of metabolic syndrome among people living with human immunodeficiency virus (PLWHIV). Diabetol. Metab. Syndr. 2018 10 1 10 10.1186/s13098‑018‑0312‑y 29483948
    [Google Scholar]
  17. Nguyen K.A. Peer N. Mills E.J. Kengne A.P. A meta-analysis of the metabolic syndrome prevalence in the global HIV-infected population. PLoS One 2016 11 3 e0150970
    [Google Scholar]
  18. Mondy K. Overton E.T. Grubb J. Tong S. Seyfried W. Powderly W. Yarasheski K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin. Infect. Dis. 2007 44 5 726 734 10.1086/511679 17278068
    [Google Scholar]
  19. SeyedAlinaghi S HIV in Iran: onset, responses, and future directions. AIDS 2021 35 4 529 542
    [Google Scholar]
  20. Shakiba M. Shokouhi S. Alaei F. Keyvanfar A. Najafiarab H. Yasaei M. Prevalence of dysglycemia, dyslipidemia, and metabolic syndrome among patients with HIV infection: A cross-sectional study from Iran. Med J Islam Repub Iran 2023 37 115
    [Google Scholar]
  21. Davoodian P. Nourozian M. The prevalence of metabolic and endocrine disorders among HIV-infected patients in a population from the South of Iran. Dis Diagn. 2022 11 1 3 9
    [Google Scholar]
  22. Evaluation and treatment of high blood cholesterol in adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001 285 2486 2496 10.1001/jama.285.19.2486 11368702
    [Google Scholar]
  23. Grundy SM Cleeman JI Daniels SR Diagnosis and management of the metabolic syndrome: An American Heart Association/National heart, lung, and blood institute scientific statement. Circulation 2005 112 17 2735 2752
    [Google Scholar]
  24. Kwiatkowska W. Knysz B. Drelichowska-Durawa J. Czarnecki M. Gąsiorowski J. Biłyk E. Karczewski M. Witkiewicz W. Subclinical carotid atherosclerosis and cardiovascular risk factors in HIV-infected patients. Postepy Hig. Med. Dosw. 2011 65 770 783 10.5604/17322693.967075 22173442
    [Google Scholar]
  25. Jericó C. Knobel H. Montero M. Ordoñez-Llanos J. Guelar A. Gimeno J.L. Saballs P. López-Colomés J.L. Pedro-Botet J. Metabolic syndrome among HIV-infected patients: Prevalence, characteristics, and related factors. Diabetes Care 2005 28 1 132 137 10.2337/diacare.28.1.132 15616246
    [Google Scholar]
  26. Estrada V. Martínez-Larrad M.T. González-Sánchez J.L. de Villar N.G.P. Zabena C. Fernández C. Serrano-Ríos M. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism 2006 55 7 940 945 10.1016/j.metabol.2006.02.024 16784968
    [Google Scholar]
  27. Samaras K. Wand H. Law M. Emery S. Cooper D. Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care 2007 30 1 113 119 10.2337/dc06‑1075 17192343
    [Google Scholar]
  28. Martin L.S. Pasquier E. Roudaut N. Vandhuick O. Vallet S. Bellein V. Bressollette L. Metabolic syndrome: A major risk factor for atherosclerosis in HIV-infected patients (SHIVA study). Presse Med. 2008 37 4 579 584 10.1016/j.lpm.2007.09.022 18313892
    [Google Scholar]
  29. Yuhana M.Y. Kamarulzaman A. Pendek R. Ismail N. The prevalence and characteristics of metabolic syndrome in urban Malaysian HIV-infected patients. Int. J. Infect. Dis. 2012 16 e195 10.1016/j.ijid.2012.05.768
    [Google Scholar]
  30. Ayodele O.E. Akinboro A.O. Akinyemi S.O. Adepeju A.A. Akinremi O.A. Alao C.A. Popoola A.A. Prevalence and clinical correlates of metabolic syndrome in Nigerians living with human immunodeficiency virus/acquired immunodeficiency syndrome. Metab. Syndr. Relat. Disord. 2012 10 5 373 379 10.1089/met.2012.0050 22799758
    [Google Scholar]
  31. Worm S.W. Lundgren J.D. The metabolic syndrome in HIV. Best Pract. Res. Clin. Endocrinol. Metab. 2011 25 3 479 486 10.1016/j.beem.2010.10.018 21663841
    [Google Scholar]
  32. van Wijk J.P.H. Cabezas M.C. Hypertriglyceridemia, metabolic syndrome, and cardiovascular disease in HIV-infected patients: Effects of antiretroviral therapy and adipose tissue distribution. Int. J. Vasc. Med. 2012 2012 1 13 10.1155/2012/201027 21876813
    [Google Scholar]
  33. Sears S. Buendia J.R. Odem S. Qobadi M. Wortley P. Mgbere O. Sanders J. Spencer E.C. Barnes A. Metabolic syndrome among people living with HIV receiving medical care in Southern United States: Prevalence and risk factors. AIDS Behav. 2019 23 11 2916 2925 10.1007/s10461‑019‑02487‑8 30929149
    [Google Scholar]
  34. Todowede O.O. Mianda S.Z. Sartorius B. Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa—a systematic review and meta-analysis. Syst. Rev. 2019 8 1 4 10.1186/s13643‑018‑0927‑y 30606249
    [Google Scholar]
  35. Ojong E. Iya B. Djeufouata J. Ndeh F. Nsonwu A. Njongang V. Etukudo M. Usoro C. Ekpo J. Metabolic syndrome and its components among HIV/AIDS patients on antiretroviral therapy and ART-Naïve patients at the University of Calabar teaching Hospital, Calabar, Nigeria. Afr. Health Sci. 2022 22 1 410 417 10.4314/ahs.v22i1.50 36032434
    [Google Scholar]
  36. Mazloomzadeh S. Rashidi Khazaghi Z. Mousavinasab N. The prevalence of metabolic syndrome in Iran: A systematic review and meta-analysis. Iran. J. Public Health 2018 47 4 473 480 29900131
    [Google Scholar]
  37. Assefa A. Abiye A.A. Tadesse T.A. Woldu M. Prevalence and factors associated with dyslipidemia among people living with HIV/AIDS on follow-up care at a tertiary care hospital in Ethiopia: A cross-sectional study. Drug Healthc. Patient Saf. 2023 15 93 102 10.2147/DHPS.S395037 37546170
    [Google Scholar]
  38. Muyanja D. High prevalence of metabolic syndrome and cardiovascular disease risk among people with HIV on stable ART in Southwestern uganda. AIDS Patient Care STDS 2016 30 1 4 10 10.1089/apc.2015.0213
    [Google Scholar]
  39. Møller S.P. Amare H. Christensen D.L. Yilma D. Abdissa A. Friis H. Faurholt-Jepsen D. Olsen M.F. HIV and metabolic syndrome in an Ethiopian population. Ann. Hum. Biol. 2020 47 5 457 464 10.1080/03014460.2020.1781929 32683894
    [Google Scholar]
  40. Kajogoo V.D. Gorret Atim M. Amare D. Geleta M. Muchie Y. Tesfahunei H.A. Olomi W. Acam J. Manyazewal T. HIV protease inhibitors and insulin sensitivity: A systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol. 2021 12 635089 10.3389/fphar.2021.635089 34790115
    [Google Scholar]
  41. Kajogoo V.D. Amogne W. Medhin G. New onset type 2 diabetes mellitus risks with integrase strand transfer inhibitors-based regimens: A systematic review and meta-analysis. Metabol Open 2023 17 100235 10.1016/j.metop.2023.100235
    [Google Scholar]
  42. Shah S. Hill A. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy. Curr. Opin. Infect. Dis. 2021 34 1 16 24 10.1097/QCO.0000000000000695 33278177
    [Google Scholar]
  43. Crum-Cianflone N. Roediger M.P. Eberly L. Headd M. Marconi V. Ganesan A. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One 2010 5 4 e10106
    [Google Scholar]
  44. Nalugga E.A. Laker E. Nabaggala M.S. Ddungu A. Batte C. Piloya T. Bongomin F. Prevalence of overweight and obesity and associated factors among people living with HIV attending a tertiary care clinic in Uganda. BMC Nutr. 2022 8 1 107 10.1186/s40795‑022‑00604‑w 36167612
    [Google Scholar]
  45. Chițu-Tișu C.E. Barbu E.C. Lazăr M. Bojincă M. Tudor A.M. Hristea A. Abagiu A.O. Ion D.A. Bădărău A.I. Body composition in HIV-infected patients receiving highly active antiretroviral therapy. Acta Clin. Belg. 2017 72 1 55 62 10.1080/17843286.2016.1240426 27724840
    [Google Scholar]
  46. Aurpibul L. Namwongprom S. Sudjaritruk T. Ounjaijean S. Metabolic syndrome, biochemical markers, and body composition in youth living with perinatal HIV infection on antiretroviral treatment. PLoS One 2020 15 3 e0230707 10.1371/journal.pone.0230707
    [Google Scholar]
/content/journals/chr/10.2174/011570162X340090250204072449
Loading
Prevalence of Metabolic Syndrome in Iranian Adults Receiving Antiretroviral Treatment for HIV
Bentham Science Publishers ; https://doi.org/10.2174/011570162X340090250204072449
/content/journals/chr/10.2174/011570162X340090250204072449
/content/journals/chr/10.2174/011570162X340090250204072449
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: HIV ; Metabolic Syndrome ; Iran ; Abdominal Obesity ; Obesity ; Waist circumference ; AIDS

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test